About Office Hours
Boehringer Ingelheim Office Hours mentors early-stage life-science companies providing access to expertise, an industry perspective and feedback.
Search
New partnership to develop schizophrenia treatments
Boehringer Ingelheim partners with Sosei Heptares to develop next generation schizophrenia treatments
FDA-Fast-Track-chronic-kidney-disease
FDA grants Fast Track designation for the treatment of chronic kidney disease, underscoring urgent need for new treatments for people living with the condition
Brigitte Fuhr
Brigitte Fuhr, our Head of Central Data Science, joined our team to make millions of lives better. Now she’s working on a global program that will transform our ability to develop ground-breaking treatments.
Winners of BVDzero Scholarship Programme
Boehringer Ingelheim announces winners of BVDzero Scholarship Programme
New vaccine against Bovine Respiratory Disease
Boehringer Ingelheim’s Bovalto Respi Intranasal is a new respiratory vaccine for active immunization of cattle against Bovine Respiratory Disease.
Official partner to Cat Care for Life
Boehringer Ingelheim announces its new partnership with the CatCareforLife program.
Survey with Ipsos to gain insights human-animal bond
Boehringer Ingelheim partnered with the Ipsos Research Institute to carry out a survey to explore the human-animal bond.
Approval for Aservo EquiHaler equine asthma therapy
Boehringer Ingelheim receives approval for Aservo® EquiHaler®, industry first equine asthma therapy
Avian influenza 5 things you should know
Communities across the globe are faced with outbreaks of bird flu. We stand with poultry farmers and veterinarians and supports the effort against the disease
Hypertension
Click here for more information on Hypertension
DCRI-collaboration-empact-mi
Collaboration with Duke Clinical Research Institute on EMPACT-MI trial, which will assess outcomes in people who have had a myocardial infarction
Rethinking mental health care
Outdated perceptions and practices fuelling mental health crisis, new Economist Impact study reveals
Spesolimab prevents GPP flares
Spesolimab prevents generalized pustular psoriasis flares in EFFISAYIL™ 2 trial
CHMP recommends conditional approval for first GPP treatment
CHMP recommends conditional marketing authorization for novel IL-36 receptor monoclonal antibody, spesolimab, as first treatment for generalized pustular psoriasis flares
Collaboration to fight NCDs
70 percent of global deaths are attributable to NCDs and severely impacting on people in low- and middle-income countries. Help is desperately needed.
Solidarity with Ukraine
Our company condemns the military aggression against Ukraine and is committed to helping those in need in the longer term with monetary and in kind donations
Odile Bain Memorial Prize 2021
Brilliant early-career scientists in parasitology recognized
Collaborating for social impact
Societal challenges require collective action and Making More Health Together is connecting changemakers to drive collaborations for more social impact
2018 Animal Welfare Medals
2018 Animal Welfare Medals: Boehringer Ingelheim recognizes outstanding research in cattle, equine, swine, as well as small animals and pet categories
Partnership to further develop pet market in China
Boehringer Ingelheim invests in partnership to further develop the pet market in China, acquires a stake in New Ruipeng Group
Dirk Stenkamp
Dirk Stenkamp, Senior Vice President Research Site Germany, reflects on our culture of collaboration and passion for progress.
environmental sustainability commitments
On the occasion of the 2021 UN Climate Change Conference (COP26), Boehringer Ingelheim shares an update on its strategic approach to sustainability
Our Venture Fund on the search for groundbreaking trends
The Boehringer Ingelheim Venture Fund acquires minority stakes in biotech start-ups, and even supports the majority before and during their founding.
Positive-CHMP-opinion-for-dabigatran-in-children
Positive CHMP opinion received for use of dabigatran for the treatment and prevention of venous thromboembolic events in children